Roche has halted development on two of its Huntington’s disease prospects, delivering another blow to a patient community that has long awaited new medicines. The Swiss drugmaker explained its ...

Fate Therapeutics has seen improvements in 4 patients with treatment-resistant systemic sclerosis who were dosed with it | ...

GSK has walked away from a $2.2 billion biobucks neurodegenerative disease pact with Alector that has seen both drugs ...

The FDA has paused a controversial policy of releasing letters describing its rationale for rejecting drugs, Fierce Biotech ...

Satellos Bioscience has shared evidence that its Duchenne muscular dystrophy (DMD) drug candidate is active in adults, ...

Prime Medicine has come out ahead in its patent dispute with fellow gene editing biotech Beam Therapeutics, after a panel of ...

AstraZeneca is paying Sino Biopharmaceutical $200 million upfront for ex-China rights to a late-phase challenger to Merck & ...

The merged entity will retain the Scipher brand and take advantage of Chemomab’s Nasdaq listing, although the ticker will ...

Clinical-stage biotech Kalohexis is preparing for a public listing to support its obesity and cancer cachexia treatments. | ...

Boehringer Ingelheim has landed an exclusive license to Prime Vector Technologies’ (PVT) viral vector platform for developing ...

As U.S. lawmakers continue to scrutinize the consequences of China’s expanding role in biotech innovation, industry insiders ...

Phase 3 trials of Kailera Therapeutics’ oral GLP-1 prospect have hit their primary endpoints, positioning the biotech’s ...